BTF's 2024 Updates on Hematology and Oncology, Houston

Houston, TX US
July 27, 2024 to July 28, 2024

This CME-accredited oncology conference, BTF's 2024 Updates on Hematology and Oncology, Houston, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

The expert faculty will present a comprehensive overview of recent updates in hematology and oncology. The program will feature in-depth discussions and analyses of the latest scientific discoveries and advancements. Faculty will contextualize these findings within clinical practice and explore their potential to alter current standards of care. This conference is designed for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals, providing them with the latest updates in the field. Emphasizing a multidisciplinary approach, it will showcase the integration of new advancements into patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

Organizing Committee: 

Course Director:

Binay Shah, MD, MHA - Binaytara Foundation

Co-Chairs:

Banu Arun, MD - MD Anderson Cancer Center

Shilpan Shah, MD - Houston Methodist

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  2. Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  3. Explain how to effectively manage side-effects associated with cancer treatment

HOTEL INFORMATION

A limited number of rooms have been booked at the Houston Marriott Medical Center/Museum District at a discounted nightly rate of $179 per room for this conference's attendees and sponsors. Please book your room at the link here by June 27, 2024 to receive the discounted group rate.  

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 10.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.00 Contact Hours.
Course opens: 
11/07/2023
Course expires: 
09/06/2024
Event starts: 
07/27/2024 - 8:00am PDT
Event ends: 
07/28/2024 - 12:15pm PDT
Cost:
$350.00

DAY 1 - JULY 27th, 2024


All times below are listed in Central Time (CT).

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:20 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:20 AM – 09:50 AM  Session 1 - Hematologic Malignancies

Session Chair: Shilpan Shah, MD

08:20 AM – 08:50 AM  MDS/Leukemias - Hahn Mai, DO

08:50 AM – 09:20 AM  Multiple Myeloma - Siddhartha Ganguly, MD

09:20 AM – 09:50 AM  Lymphoma & CLL - Sai Pingali, MD


09:50 AM – 10:20 AM  Break & Exhibits


10:20 AM – 11:50 AM  Session 2 - Thoracic Oncology

Session Chair: Jun Zhang, MD

10:20 AM – 10:50 AM  Early-Stage NSCLC - Ryan Kieser, MD

10:50 AM – 11:20 AM  Metastatic NSCLC - Meera Patel, MD

11:20 AM – 11:50 AM  Small Cell Lung Cancer - Ethan Burns, MD


11:50 AM – 12:50 PM  Lunch & Exhibits

12:00 PM – 12:45 PM - Product Theater Sponsored by Merck in conference rooms 3-5

Topic: A Treatment Option for Adult Patients With Locally Advanced or Metastatic Urothelial Cancer

Speaker: Luis Camacho, MD

* This is a non-CME activity *


12:50 PM – 02:30 PM  Session 3 - Case-Based Presentations 1

Session Chair: Devesh Pandya, MD

12:50 PM – 01:10 PM  Case 1: Sarcoma - Aparna Chakravarti Jotwani, MD

01:10 PM – 01:30 PM  Case 2: Brain Tumor Updates - Vyshak Venur, MD

01:30 PM – 01:50 PM  Case 3: Acute Leukemia - Martha Mims, MD

01:50 PM – 02:10 PM  Case 4: Cellular Therapy - Vikram Dhillon, DO, MBA

02:10 PM – 02:30 PM  Case 5: GU Cancer - Shubham Adroja, MD


02:30 PM – 03:15 PM  Break & Exhibits


03:15 PM – 04:45 PM  Session 4 - Genitourinary Cancer 

Session Chair: Nizar Tannir, MD

03:15 PM – 03:45 PM  Prostate Cancer - Bilal Siddiqui, MD

03:45 PM – 04:15 PM  Bladder Cancer - Omar Alhalabi, MD

04:15 PM – 04:45 PM  Kidney Cancer - Nizar Tannir, MD


DAY 2 - JULY 28th, 2024
 

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 09:00 AM  Session 5 - Case-Based Presentations 2

Session Chair: Pavel Levin, MD, PhD

08:00 AM – 08:15 AM  Case 1: Gynecologic Cancer - Zainub Ajmal, MD

08:15 AM – 08:30 AM  Case 2: Breast Cancer - Darya Kizub, MD

08:30 AM – 08:45 AM  Case 3: Pancreatic Cancer - Dan Zhao, MD

08:45 AM – 09:00 AM  Case 4: Breast Cancer - Yuan Gao, MD


09:00 AM – 10:30 AM  Session 6 - GI Cancer

Session Chair: Sunyoung S. Lee, MD

09:00 AM – 09:30 AM  Colorectal Cancer - Christine M. Parseghian, MD

09:30 AM – 10:00 AM  Hepatobiliary and Pancreatic Malignancies - Shalini Makawita, MD

10:00 AM – 10:30 AM  Upper GI Cancer - Anaum Maqsood, MD


10:30 AM – 10:45 AM  Break & Exhibits


10:45 AM – 12:15 PM  Session 7 - Breast Cancer

Session Chair: Banu Arun, MD

10:45 AM – 11:15 AM  Hormone Receptor Positive Breast Cancer - Julie R. Nangia, MD

11:15 AM – 11:45 AM  HER2 Positive Breast Cancer - Polly Niravath, MD

11:45 AM – 12:15 PM  Triple Negative Breast Cancer - Clinton Yam, MD


12:15 PM   Adjourn

Houston Marriott Medical Center/Museum District
6580 Fannin St
Houston, TX 77030
United States

A limited number of rooms have been booked at the Houston Marriott Medical Center/Museum District at a discounted nightly rate of $179 per room for this conference's attendees and sponsors. Please book your room at the link here by June 27, 2024 to receive the discounted group rate.  

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Banu Arun

has a financial relationship (Other) with Astra Zeneca;.

Shilpan Shah

has no relevant financial relationships to disclose at this time.
Session Chair(s)

Sunyoung Lee, MD, PhD

has no relevant financial relationships to disclose at this time.

Pavel Levin

has a financial relationship (Professional Services) with AstraZeneca;.

Nizar Tannir, MD

has a financial relationship (Professional Services) with Bristol-Myers-Squibb;.
has a financial relationship (Professional Services) with Merck Sharp & Dohme;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with lntellisphere;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Oncorena;.
has a financial relationship (Professional Services) with Eisai Medical Research;.
has a financial relationship (Professional Services) with Nektar Therapeutics;.

Jun Zhang, MD

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Omar Alhalabi, MD

has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Other) with Seagen;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Ikena;.
has a financial relationship (Other) with Cardinal health;.
has a financial relationship (Grant Or Contract) with Arcus;.
has a financial relationship (Other) with Silverback;.

vyshak Alva Venur

has no relevant financial relationships to disclose at this time.

Ethan Burns, MD

has no relevant financial relationships to disclose at this time.

Siddhartha Ganguly, MD, FACP

has a financial relationship (Financial Support) with Sanofi Genzyme;.
has a financial relationship (Financial Support) with Kite Pharma;.
has a financial relationship (Financial Support) with Astra Zeneca;.

Aparna Jotwani

has no relevant financial relationships to disclose at this time.

Shalini Makawita

has no relevant financial relationships to disclose at this time.

Julie Nangia, MD

has no relevant financial relationships to disclose at this time.

Polly Niravath, MD

has a financial relationship (Independent contractor) with Amplity Health;.
has a financial relationship (Independent contractor) with Novartis;.

Christine Parseghian, MD

has no relevant financial relationships to disclose at this time.

Meera Patel, MD, MHS

has no relevant financial relationships to disclose at this time.

Sai Ravi Pingali

has a financial relationship (Professional Services) with Cardinal Health;.

Bilal Siddiqui, MD

has a financial relationship (Travel) with Regeneron;.

Nizar Tannir, MD

has a financial relationship (Professional Services) with Bristol-Myers-Squibb;.
has a financial relationship (Professional Services) with Merck Sharp & Dohme;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with lntellisphere;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Oncorena;.
has a financial relationship (Professional Services) with Eisai Medical Research;.
has a financial relationship (Professional Services) with Nektar Therapeutics;.

Clinton Yam, MD, MS

has a financial relationship (Grant Or Contract) with Gilead - funding to the institution;.
has a financial relationship (Grant Or Contract) with GlaxoSmithKline Oncology - funding to the institution;.
has a financial relationship (Grant Or Contract) with BostonGene - funding to the institution;.
has a financial relationship (Grant Or Contract) with Genentech - funding to the institution;.
has a financial relationship (Grant Or Contract) with Amgen - funding to the institution;.
has a financial relationship (Grant Or Contract) with Merck - funding to the institution;.
has a financial relationship (Travel) with Gilead - for advisory board;.
Case Presenter(s)

Shubham Adroja

has no relevant financial relationships to disclose at this time.

Zainub Ajmal, MD

has no relevant financial relationships to disclose at this time.

Vikram Dhillon, DO, MBA

has no relevant financial relationships to disclose at this time.

Yuan Gao

has no relevant financial relationships to disclose at this time.

Darya Kizub, MD

has no relevant financial relationships to disclose at this time.

dan zhao, MD, PhD

has a financial relationship (Grant Or Contract) with TriSalus;.
has a financial relationship (Grant Or Contract) with Mirati;.
has a financial relationship (Grant Or Contract) with CARsgen;.
has a financial relationship (Grant Or Contract) with Affini-T;.
has a financial relationship (Other) with Ipsen;.

Available Credit

  • 10.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme .

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.